Forest Lboratories news from FierceBiotech
NewsALSO NOTED: FDA OKs Novalar therapy; StemCells files new patent suit; and much more...
> The FDA has OK'd Novalar's OraVerse (phentolamine mesylate) for the reversal of soft-tissue anesthesia and the associated functional deficits resulting from a local dental anesthetic. Read more...
ALSO NOTED: Endo buys Novartis' Voltaren; Microbia, Forest produce positive Phase III data; and much more...
> Endo Pharmaceutical is buying Novartis' Voltaren gel for $85 million upfront and a one-time sales milestone of $25 million. Read more...
ALSO NOTED: Sirtris, NCI collaborate on cancer models; Kylin expands in Indiana; and much more...
> Sirtris announced a collaboration with the National Cancer Institute to its enzyme activators in cancer models. Read more...
ALSO NOTED: GTC announces positive ATryn data; NC biotech center to expand; FDA delays Requip XL decision; and much more...
> Shares of GTC Biotherapeutics were buoyed after the company announced positive results from a late-stage study of ATryn among patients with hereditary antithrombin deficiency undergoing Read more...
Forest inks $219M deal for combo drug program
Forest Laboratories has put up $109.6 million to snare development rights to Novexel's intravenous beta lactamase inhibitor, NXL 104, in combination with Forest's ceftaroline. And Forest could pay Read more...
ALSO NOTED: Paion inks $102M deal; Sepracor chairman plans retirement years;and much more...
> Sepracor Chairman Timothy Barberich is planning to retire. He will receive $1.65 million a year under a retirement pact. Read more...
New "me-too" beta blocker dissed by experts
The Wall Street Journal health blog pokes fun at Bystolic, the Read more...
ALSO NOTED: Burrill bullish on M&As; Nebivolol wins approval; Arrowhead Research names CEO; and much more...
> G. Steven Burrill is touting the (relative) success of his Burrill Biotech Select Index compared to the swooning Nasdaq and sounds quite bullish about the impact of Read more...
ALSO NOTED: Novartis plots $700M biotech plant; Genzyme wins marketing approval; Glenmark, Forest to pursue Phase II; and much
> Novartis will plow $700 million into a new cell-culturing facility in Singapore. The plant will boost the drug maker's capacity for biotech drugs, delivering products for commercial distribution Read more...
| Press ReleasesPRESS RELEASE: Forest Laboratories High Dose of Schizophrenia Drug Doesn't Meet Goal Forest Laboratories High Dose of Schizophrenia Drug Doesn't Meet Goal NEW YORK and BUDAPEST, Hungary, Oct. 15 -- Forest Laboratories and Gedeon Richter today announced preliminary top-line results Read more... PRESS RELEASE: Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration CAMBRIDGE, Mass. and NEW YORK, Sept. 17 -- Microbia, Inc. and Forest Laboratories, Inc. , today Read more... PRESS RELEASE: Forest Laboratories Announces Federal Appeals Court Upholds Lexapro Patent Decision Forest Laboratories Announces Federal Appeals Court Upholds Lexapro Patent Decision NEW YORK, Sept. 5 -- Forest Laboratories and H. Lundbeck A/S of Denmark said today that the U.S. Court of Appeals Read more... PRESS RELEASE: PAION's Partner Forest Terminates Co-development On Desmoteplase PAION's Partner Forest Terminates Co-development On Desmoteplase Aachen, Germany, Aug 30, 2007 - Aachen (Germany), 30 August 2007 - PAION AG (Frankfurt Stock Exchange, Prime Standard: PA8) today Read more... |
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets